PDS Historical Financial Ratios
| PDSB Stock | USD 1.25 0.01 0.81% |
PDS Biotechnology is promptly reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 547, Invested Capital of 0.0, Average Payables of 2.1 M or Stock Based Compensation To Revenue of 0.0 will help investors to properly organize and evaluate PDS Biotechnology Corp financial condition quickly.
PDS |
About PDS Financial Ratios Analysis
PDS Biotechnology CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate PDS Biotechnology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on PDS financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across PDS Biotechnology history.
PDS Biotechnology Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from PDS Biotechnology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into PDS Biotechnology Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At present, PDS Biotechnology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 547.42, whereas Free Cash Flow Yield is projected to grow to (560.08).
PDS Biotechnology fundamentals Correlations
Click cells to compare fundamentals
PDS Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PDS Biotechnology fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 1.32 | 3.28 | 8.58 | 5.89 | 0.003126 | 0.003283 | |
| Book Value Per Share | 1.62 | 2.47 | 1.54 | 0.84 | 521.36 | 547.42 | |
| Free Cash Flow Yield | (0.37) | (0.0602) | (0.0681) | (0.22) | (589.56) | (560.08) | |
| Operating Cash Flow Per Share | (0.79) | (0.49) | (0.9) | (1.09) | (960.98) | (912.93) | |
| Pb Ratio | 1.32 | 3.28 | 8.58 | 5.89 | 0.003126 | 0.003283 | |
| Free Cash Flow Per Share | (0.79) | (0.49) | (0.9) | (1.09) | (960.98) | (912.93) | |
| Roic | (1.71) | (0.53) | (0.27) | (0.83) | (0.91) | (0.96) | |
| Net Income Per Share | (0.89) | (0.66) | (1.43) | (1.39) | (1.1K) | (1.0K) | |
| Payables Turnover | 0.12 | 0.19 | 0.0403 | 0.00821 | 0.007389 | 0.007019 | |
| Cash Per Share | 1.72 | 2.55 | 2.58 | 1.83 | 1.1K | 1.2K | |
| Pocfratio | (2.73) | (16.61) | (14.68) | (4.57) | (0.001696) | (0.001781) | |
| Interest Coverage | (30.24) | (626.8) | (31.65) | (10.23) | 7.77 | 8.16 | |
| Pfcf Ratio | (2.73) | (16.61) | (14.68) | (4.57) | (0.001696) | (0.001781) | |
| Days Payables Outstanding | 2.9K | 1.9K | 9.1K | 44.5K | 40.0K | 42.0K | |
| Income Quality | 0.89 | 0.74 | 0.63 | 0.78 | 0.93 | 0.75 | |
| Roe | (0.55) | (0.27) | (0.93) | (1.64) | (2.07) | (1.97) | |
| Ev To Operating Cash Flow | (0.58) | (11.42) | (12.73) | (3.6) | 0.83 | 0.87 | |
| Pe Ratio | (2.41) | (12.26) | (9.24) | (3.58) | (0.00151) | (0.001586) | |
| Ev To Free Cash Flow | (0.58) | (11.42) | (12.73) | (3.6) | 0.83 | 0.87 | |
| Earnings Yield | (4.08) | (0.54) | (0.41) | (0.0816) | (662.24) | (629.12) | |
| Net Debt To E B I T D A | 1.68 | 1.92 | 3.06 | 0.82 | 0.8 | 0.76 | |
| Current Ratio | 9.28 | 17.8 | 7.79 | 4.33 | 2.64 | 2.5 | |
| Tangible Book Value Per Share | 1.62 | 2.47 | 1.54 | 0.84 | 521.36 | 547.42 | |
| Shareholders Equity Per Share | 1.62 | 2.47 | 1.54 | 0.84 | 521.36 | 547.42 | |
| Graham Net Net | 1.5 | 2.39 | 1.43 | 0.75 | 420.7 | 441.74 | |
| Interest Debt Per Share | 0.0364 | 0.0192 | 0.87 | 0.91 | 218.09 | 228.99 | |
| Enterprise Value Over E B I T D A | (0.1) | (0.52) | (6.73) | (7.86) | (3.02) | 0.8 | |
| Price Earnings Ratio | (2.41) | (12.26) | (9.24) | (3.58) | (0.00151) | (0.001586) | |
| Price Book Value Ratio | 1.32 | 3.28 | 8.58 | 5.89 | 0.003126 | 0.003283 | |
| Price Earnings To Growth Ratio | 0.0195 | 0.0632 | 0.47 | (0.0792) | 1.28 | 0.0 | |
| Days Of Payables Outstanding | 2.9K | 1.9K | 9.1K | 44.5K | 40.0K | 42.0K | |
| Price To Operating Cash Flows Ratio | (2.73) | (16.61) | (14.68) | (4.57) | (0.001696) | (0.001781) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.